Product Information
ASTAGRAF XL 1 MG CAPSULE is a brand product labeled by Astellas Pharma US, Inc., priced at $5.7091 per EA under NDC 00469067773. Its NADAC has been published 350 times since Jan 22, 2020.
FDA first approved this application on Jul 19, 2013. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
1 mg/1
Manufacturer
Astellas Pharma US, Inc.NDC
00469067773
Classification
Brand
Dosage Form
CAPSULE, COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TACROLIMUSApproval Type
New Drug (NDA)
FDA Application
NDA204096FDA Approved
7/19/2013
TE Code
AB
On Market Since
7/19/2013
Pharmacological Classes
Price Statistics
The NADAC for ASTAGRAF XL 1 MG CAPSULE has been published 350 times since Jan 22, 2020, and over the history we have for it it has risen 25.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $5.7091 per EA |
|---|---|
| All-time high | $5.7091 (Sep 30, 2026) |
| All-time low | $4.5486 (Jan 22, 2020) |
| 52-week high | $5.7091 |
| 52-week low | $5.4946 |
| Median price | $5.2591 |
| Average price | $5.1309 |
| Largest weekly change | +6.0% (Jan 25, 2023) |
| Weeks tracked | 350 |
| Tracking since | Jan 22, 2020 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the tacrolimus extended-release capsules market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Astellas Pharma US, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
tacrolimus extended-release capsules market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcineurin Inhibitor Immunosuppressant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ASTAGRAF XL 1 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for ASTAGRAF XL 1 MG CAPSULE, manufactured by Astellas Pharma US, Inc., is $5.7091 per EA (NDC 00469067773), effective Sep 30, 2026.
How has the price of ASTAGRAF XL 1 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for ASTAGRAF XL 1 MG CAPSULE has risen 25.5%. It has been tracked across 350 weekly CMS publications since Jan 22, 2020.
What are the highest and lowest recorded NADAC prices for ASTAGRAF XL 1 MG CAPSULE?
Since Jan 22, 2020, the NADAC for ASTAGRAF XL 1 MG CAPSULE has ranged from a low of $4.5486 (Jan 22, 2020) to a high of $5.7091 (Sep 30, 2026), with a median of $5.2591 per EA.
Are there cheaper alternatives to ASTAGRAF XL 1 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of ASTAGRAF XL 1 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ASTAGRAF XL 1 MG CAPSULE?
ASTAGRAF XL 1 MG CAPSULE (NDC 00469067773) is labeled by Astellas Pharma US, Inc., and CMS classifies it as a brand product.